Vaccinations for healthcare personnel: Update on influenza, hepatitis B, and pertussis

Current Opinion in Infectious Diseases

Volumn 26, Issue 4, 2013, Pages 366-377

  Kaltsas, Anna ^a   Sepkowitz, Kent ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

healthcare personnel; healthcare workers; hepatitis B; immunization; influenza; pertussis; vaccination

Indexed keywords

ACELLULAR VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; NON EGG BASED VACCINE; PERTUSSIS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBODY RESPONSE; ARTHRITIS; BRAIN DISEASE; CD4 LYMPHOCYTE COUNT; CHICKENPOX; DIPHTHERIA; DRUG EFFICACY; DRUG MEGADOSE; ENCEPHALITIS; FEBRILE CONVULSION; HEALTH CARE PERSONNEL; HEPATITIS; HEPATITIS B; HERPES ZOSTER; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INFLUENZA; INFLUENZA A; INFLUENZA B; LIMB PAIN; LIMB SWELLING; LONG TERM CARE; MEASLES; MENINGOCOCCOSIS; MUMPS; NONHUMAN; NOSE OBSTRUCTION; PERIPHERAL EDEMA; PERTUSSIS; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINORRHEA; RUBELLA; SEROCONVERSION; SEROPREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW (TOPIC); TETANUS; THROMBOCYTOPENIA; VACCINATION; VACCINE FAILURE; VIRUS REPLICATION; VIRUS SHEDDING;

COMMUNICABLE DISEASE CONTROL; HEPATITIS B; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; INFLUENZA, HUMAN; VACCINATION; VACCINES; WHOOPING COUGH;

EID: 84879886608     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283630ee5     Document Type: Review

References (81)

1. Ehreth J. The global value of vaccination. Vaccine 2003; 21 (7-8):596-600. (Pubitemid 36091966)
2. Fiore AE, Shay DK, Haber P, et al. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recomm Rep 2011; 60:1-45.
3. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2010; 1-60.
4. Cherry JD. The present and future control of pertussis. Clin Infect Dis 2010; 51:663-667.
5. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-1340. (Pubitemid 39223224)
6. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-1436.
7. Tsagris V, Nika A, Kyriakou A, et al. Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit. J Hosp Infect 2012; 81:36-40.
8. Chan MCW, Lee N, Ngai KLK, et al. A ''preseasonal'' hospital outbreak of influenza pneumonia caused by the drift variant A/Victoria/361/2011-like H3N2 viruses, Hong Kong, 2011. J Clin Virol 2013; 56:303-309.
9. Sayers G, Igoe D, Carr M, et al. High morbidity and mortality associated with an outbreak of influenza A(H3N2) in a psycho-geriatric facility. Epidemiol Infect 2013; 141:357-365.
10. Salgado CD, Farr BM, Hall KK, et al. Influenza in the acute hospital setting. Lancet Infect Dis 2002; 2:145-155. (Pubitemid 34462449)
11. Hofmann F, Ferracin C, March G, et al. Influenza vaccination of healthcare workers: a literature review of attitudes and beliefs. Infection 2006; 34:142-147. (Pubitemid 43979662)
12. Vanhems P, Voirin N, Roche S, et al. Risk of influenza-like illness in an acute healthcare setting during community influenza epidemics in 2004-2005, 2005-2006, and 2006-2007: a prospective study. JAMA Intern Med 2011; 171:151-157.
13. Oguma T, Sait R, Masaki H, et al. Molecular characteristics of outbreaks of nosocomial infection with influenza A/H3N2 virus variants. Infect Control Hosp Epidemiol 2011; 32:267-275.
14. Wendelboe AM, Avery C, Andrade B, et al. Importance of employee vaccination against influenza in preventing cases in long-term care facilities. Infect Control Hosp Epidemiol 2011; 32:990-997.
15. Benet T, Regis C, Voirin N, et al. Influenza vaccination of healthcare workers in acute-care hospitals: a case-control study of its effect on hospital-acquired influenza among patients. BMC Infect Dis 2012; 12:30.
16. Dolan GP, Harris RC, Clarkson M, et al. Vaccination of healthcare workers to protect patients at increased risk for acute respiratory disease. Emerg Infect Dis 2012; 18:1225-1234.
17. Mytton OT, O'Moore EM, Sparkes T, et al. Knowledge, attitudes and beliefs of healthcare workers towards influenza vaccination. Occupation Med 2013; 63:189-195.
18. Ansaldi F, de Florentiis D, Durando P, et al. Fluzone Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012; 11:17-25.
19. Foy JE, Hendriksz T, Malouf P, et al. Acceptability of Fluzone Intradermal vaccine to patients and vaccine administrators. J Am Osteopath Assoc 2013; 113:134-143.
20. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8:81-88.
21. Greenberg DP, Robertson CA, Noss MJ, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31:770-776.
22. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. Epub ahead of print, 18 April 2013. J Infect Dis 2013; Epub ahead of print, 18 April 2013.
23. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-1998.
24. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30:7443-7446.
25. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-696.
26. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44.
27. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-1267.
28. Block SL, Yogev R, Hayden FG, et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008; 26:4940-4946.
29. Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005; 26:494-500. (Pubitemid 40695285)
30. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of coldadapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590-595; 10.097/01.inf.0000220229.51531.47. (Pubitemid 43995354)
31. Jackson LA, Holmes SJ, Mendelman PM, et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999; 17 (15-16):1905-1909. (Pubitemid 29172359)
32. King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)- infected and non-HIV-infected adults. J Infect Dis 2000; 181:725-728. (Pubitemid 30131847)
33. Carr S, Allison KJ, Van de Velde LA, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011; 204:1475-1482.
34. Halasa N, Englund J, Nachman S, et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011; 29:4110-4115.
35. Talbot TR, Babcock H, Cotton D, et al. The use of live attenuated influenza vaccine (LAIV) in healthcare personnel (HCP): guidance from the society for healthcare epidemiology of America (SHEA). Infect Control Hosp Epidemiol 2012; 33:981-983.
36. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004.
37. Harper D, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Obstet Gynecol Survey 2004; 364:1757-1765. (Pubitemid 39488060)
38. McPherson CE. Development of a novel recombinant influenza vaccine in insect cells. Biologicals 2008; 36:350-353. (Pubitemid 50274118)
39. Groth N, Montomoli E, Gentile C, et al. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-791.
40. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-848.
41. Vesikari T, Block SL, Guerra F, et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012; 31:494-50010. 097/INF.0b013e31824bb179
42. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok1 trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272-2278.
43. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok1) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29: 7733-7739.
44. Olyarchuk LD, Willoughby D, Newsom SA, et al. Examining the benefit of vaccinating adults against pertussis. J Am Acad Nurse Pract 2012; 24:587-594
45. Elumogo TN, Booth D, Enoch DA, et al. Bordetella pertussis in a neonatal intensive care unit: identification of the mother as the likely source. J Hosp Infect 2012; 82:133-135.
46. Yasmin S, Sunenshine R, Bisgard KM, et al. Healthcare-associated pertussis outbreak in Arizona: challenges and economic impact, 2011. J Pediatr Infect Dis 2013; Published online Jan 30, 2013.
47. Ward A, Caro J, Bassinet L, et al. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 2005; 26:288-292. (Pubitemid 40445088)
48. Baggett HC, Duchin JS, Shelton W, et al. Two nosocomial pertussis outbreaks and their associated costs - King County, Washington, 2004. Infect Control Hosp Epidemiol 2007; 28:537-543. (Pubitemid 46814542)
49. Cherry JD. Epidemic Pertussis in 2012 - the resurgence of a vaccinepreventable disease. N Engl J Med 2012; 367:785-787.
50. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656-661.
51. Le Saux N, Barrowman NJ, Moore DL, et al. Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT. Pediatrics 2003; 112:e348.
52. Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105:e12.
53. Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012; 129:968-970.
54. WittMA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; Published online March 2013.
55. Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT Study. J Infect Dis 2004; 190:535-544.
56. Riffelmann M, Littmann M, Hulbe C, et al. Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine. Eur J Clin Microbiol Infect Dis 2009; 28:275-279.
57. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004; 38:591-594. (Pubitemid 38250973)
58. Petersen RF, Dalby T, Dragsted DM, et al. Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg Infect Dis 2012; 18: 767-774.
59. van Gent M, Bart MJ, van der Heide HGJ, et al. Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS ONE 2012; 7:e46407.
60. Mertsola J, van der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51:656-662.
61. Hviid A, Stellfeld M, Andersen PH, et al. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine 2004; 22:3530-3534. (Pubitemid 39099630)
62. Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012; 56:422-433.
63. Oren I, Hirshow RC, Ben-Porath E, et al. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med 1989; 110:691-698. (Pubitemid 19121222)
64. Hutin YJF, Goldstein ST, Varma JK, et al. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol 1999; 20:731-735.
65. Kent GP, Brondum J, Keenlyside R, et al. A large outbreak of acupunctureassociated hepatitis B. Am J Epidemiol 1988; 127:591-598.
66. Enfield KB, Sharapov U, Hall KK, et al. Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. Clin Infect Dis 2013; 56:218-224.
67. Pattison CP, Maynard JE, Berquist KR, et al. Epidemiology of hepatitis B in hospital personnel. Am J Epidemiol 1975; 101:59-64.
68. Segal HE, LLewelyn CH, Irwin G, et al. Hepatitis B antigen and antibody in the U.S. Army: prevalence in healthcare personnel. Am J Public Health 1976; 66:667-671.
69. Thomas DL, Factor SH, Kelen GD, et al. Viral hepatitis in healthcare personnel at the Johns Hopkins Hospital: The seroprevalence of and risk factors for hepatitis b virus and hepatitis c virus infection. Arch Int Med 1993; 153:1705-1712. (Pubitemid 23217877)
70. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers. Hum Vaccin Immunother 2012; 8:896-904.
71. Spradling PR, Xing J, Williams R, et al. Immunity to hepatitis B virus infection two decades after implementation of universal infant hepatitis B vaccination: the association of detectable residual antibody and response to a single hepatitis B vaccine challenge dose. Clin Vaccin Immunol 2013; 20:559-561.
72. Chaves SS, Fischer G, Groeger J, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012; 30:1644-1649.
73. Su FH, Bai CH, Chu FY, et al. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine 2012; 30:4034-4039.
74. Chen J, Liang Z, Lu F, et al. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with nonresponse to hepatitis B vaccine. Vaccine 2011; 29:706-711.
75. Ni JD, Xiong YZ,Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS 2013; Published March 6, 2013.
76. Potsch DV, Camacho LA, Tuboi S, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012; 30:5973-5977.
77. Leonardi S, Partico AD, Lionetti E, et al. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18:5729-5733.
78. Dhillon S, Moore C, Li SD, et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination nonresponders with chronic liver disease. Dig Dis Sci 2012; 57:215-220.
79. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen coadministered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30:2556-2563.
80. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012; 30:2689-2696.
81. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology 2009; 15:137-145.